Iopidine 1%, Maxitrol available in US
Click Here to Manage Email Alerts
The new drug application transfer process for Iopidine 1%, Maxitrol 0.1% and Moxeza 0.5% is complete, Harrow Health announced in a press release. Harrow acquired the commercialization rights to the ophthalmic drops from Novartis in 2021.
In addition, Iopidine 1% (apraclonidine hydrochloride) and Maxitrol (neomycin, polymyxin B sulfate and dexamethasone) are now commercially available and can be ordered through Cardinal’s Cordlogistics, Harrow’s customer service ordering partner.
“We are pleased to have completed the transfer of the NDAs for these workhorse products, allowing us to market and sell these well-known products under the Harrow umbrella,” Mark L. Baum, CEO of Harrow Health, said in the release. “We believe there is strong interest from physicians and their patients, hospitals and ambulatory surgery centers in these products. The transfer of these NDAs gives Harrow a foundation to begin market access initiatives and lead conversations with commercial payer decision makers as we continue to execute our branded ophthalmic pharmaceuticals strategy.”
Harrow plans to commercialize Moxeza 0.5% (moxifloxacin hydrochloride) at a later date, the release said.
Read more about
Click Here to Manage Email Alerts